Slides
Page 1
20 20TH BIOSHARES BIOTECH SUMMIT 21 YEARS OF INNOVATION 2005-2026 Dimerix Approaching Inflection Points Bioshares Summit , Queenstown , NZ 6 August 2026 Authorised for lodgement by the Board of the Company Developing new therapies to treat kidney diseases with unmet clinical needs
Page 2
2 Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.
Page 3
3 From single bets to sustainable growth Diversifying for success: 1. How is Dimerix reducing its risk through diversification, both geographically and through a product portfolio? 2. What are the key attributes and value drivers that make DMX-652 an attractive licensed-in asset? 3. If DMX-200 successfully makes it to market in all currently licensed territories, what is the total in milestone payments it will receive from now until product launch in FSGS? Question posed to Dimerix:
Page 4
DIMERIX IN CONTEXT
Page 5
5 ~$1.9 billion* 5 commercial licensing partners *total upfront and potential milestone payments + royalties on net sales Phase 3 Global Opportunity 1. Based on ASX releases 05 October 2023, 27 May 2024, 07 January 2025, 01 May 2025 and 16 June 2026; SEA = Southeast Asia, G CC = Gulf Cooperation Council; 2. AS release 10 March 2026; 3. ASX release 28 April 2026; 3. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 4. ASX release 11 March 2024 and 28 April 2026; 5. ASX releases: 14 December 2015, 21 November 2018, 07 June 2021 and 30 September 2025 FSGS indication is a rare disease that causes scarring of the kidney, leading to irreversible damage3 Orphan drug designations regulatory, marketing exclusivity and pricing benefits in key territories5 5 commercial partners DMX-200 licensed USA, EU, Canada, Australia, NZ, Japan, China, S.Korea, SEA and GCC1 up to $1.9 billion in total development and sales milestone payments plus royalties on net sales1 Phase 3 trial recruitment complete in trial of DMX-200 in focal segmental glomerulosclerosis (FSGS)2 Reduced risk Proteinuria endpoint passed blinded interim (futility) assessment1 Blinded review confirmed ACTION3 statistically powered (>90%) to demonstrate statistical significance of predicted proteinuria treatment effect of DMX-2004
Page 6
6 DMX-652: Phase 2 in acute kidney injury A complementary, clinical-stage pipeline addition 1. Dimerix internal analysis; Mission Therapeutics MTX -652 development file; 2. Zarbock et al, Intensive Care Med 2023; Vervoort et al, Ann Thorac Surg 2023; 3. Dimerix internal market analysis consensus figure based on meta-analysis of 21 market reports (2026) ; Includes China and Japan markets, label expansion into sep sis-associated AKI (SA-AKI) and contrast-associated AKI Large value potential • Secured a Phase 2 ready asset, which is already FDA cleared & manufactured • Substantial work to date undertaken by originator means significant early risk already removed1 First and best in class • First-in-class USP30 target that promotes renewal of mitochondria • DMX-652 targets one of the emerging key drivers of kidney injury and reduces both cellular energy failure and inflammation Leverages existing expertise • Dimerix team are experts in kidney disease; capable of identifying high value assets • Experienced in-house team with proven track record of advancing high value assets through clinical development and into commercialisation Large and growing market • No approved therapy for high-risk acute kidney injury patients and growing demand for new therapies2 • US$3.5 Billion in 2026 • est. US$7.5 Billion by 2036 Strategic value • Dimerix has significant optionality over the development and commercialisation direction of DMX-652, as the outright asset owner • DMX-652 has the potential to be used for a variety of other indications, many of which may also have large markets and unmet medical needs
Page 7
DIVERSIFICATION BY GEOGRAPHY
Page 8
8 Beyond US & EU: growth, diversification, resilience Most biotech and pharma companies focus on the US and EU because these markets typically provide: the highest revenue potential strongest pricing power established regulatory pathways, and greatest influence on global product value 1. The Global Use of Medicines 2025: Outlook to 2029 (2025), IQVIA Institute for Human Data Science www.iqvia.com/-/media/iqvia/pdfs/events/presentation_global-meds-webinar_public.pdf However, China has become the fastest-growing major market over the past decade,1 fueled by: • an aging population; • expanded healthcare coverage; and • increasing demand for innovative medicines Japan has the highest per capita medicine use of the developed markets1
Page 9
9 Strategic rationale for multi-region development A multi-region development and partnering strategy is not only about expanding commercial opportunity, but is also a deliberate risk-management approach: Expanding Patient Access: reaching more patients in need of treatment options Revenue diversification: reduces dependence on individual region pricing reimbursement environments Economic resilience: offsets impacts of economic and regulatory uncertainty, budget cuts, or policy changes Faster clinical development: broader patient access accelerates recruitment and time-to-market Global market access: enables earlier entry into high-growth markets such as China, Japan, Middle East, and APAC Investor confidence: creates a more resilient asset with multiple growth pathways and lower concentration risk Strategic flexibility: allows prioritisation of partnerships and launches based on regional market conditions
Page 10
10 adult patient recruitment by territory Trial designed for potential approval globally Recruitment completed (adult population)1 1. ASX release 15 December 2025; 2. Final numbers of adult patients, ASX release 10 March 2026; paediatric patients will continue to recruit, and will not impact final analysis timelines 333 Adult patients recruited, randomised and dosed (target ≥286)2 Latin America Asia Pacific US / Europe
Page 11
11 Summary of licensing deals for DMX-200 to date 1. Based on US conversions & further terms outlined in ASX Announcement on 01 May 2025; 2. Based on US conversions & further terms outlined in ASX Announcement on 16 June 2026; ; 3. Based on Euro conversions & further terms outlined in ASX Announcement on 5 October 2023; 4. Based on J apanese ¥ Yen conversions & further terms outlined in ASX Announcement on 7 January 2025 ; 5. Based on US dollar conversions & further terms outlined in ASX Anno uncement on 27 May 2024 Dimerix has successfully partnered DMX-200 across multiple key markets EU, CA, AU, NZ AU$10.8 milllion3 Upfront Up to AU$219 million3 Milestones Escalating mid-teen-20% Royalties 3 GCC, Iraq AU$0.5 million5 Upfront Up to AU$120 million5 Milestones Starting at 30% Royalties 5 Japan AU$7.2 million4 Upfront + 1st milestone Up to AU$100 million4 Milestones Between 15-20% Royalties 4Licensing deals collectively valued up to ~AU$1.9 billion in total upfront and potential milestone fees plus royalties1-5 >AU$80 million in total upfront payments1-5 China,S.Korea.SEA AU$14.1 million2 Upfront Up to AU$467 million2 Milestones Between 10-15% Royalties 2 United States AU$48 million1 Upfront Up to AU$892 million1 Milestones Escalating low- teen-low twenties% Royalties 1
Page 12
12 Geographic diversification of fee revenue Collectively, five commercial agreements valued up to A$1.9 billion across upfront + milestone fees:1 Based on ASX releases 05 October 2023, 27 May 2024, 07 January 2025, 01 May 2025 and 16 June 2026 On signing Short Term Potential Longer Term Potential Diversified revenue & risk sharing with licensing partners Upfront fees Milestone Payments Milestone Payments Royalties A$81 million + A$237 million + A$1.56 billion 10 – 30 % = In licensing fees Between now and commercial launch Post commercial launch Post commercial launch Upfront and development milestones collectively A$318 million
Page 13
DIVERSIFICATION BY ASSET
Page 14
14 A first-in-class, oral, once-daily USP30 inhibitor for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery Diversifying by asset: introducing DMX-652 Small molecule New chemical entity; oral capsule formulation; GMP- grade API available to support Phase 2 clinical trial Once-daily dosing Convenient dosing schedule to provide pre-operative and post operative USP30 inhibition Well tolerated Phase 1 multi-part study completed in 109 healthy volunteers, (85 volunteers administered DMX-652) no serious adverse events and wide therapeutic margin Phase 2 ready IND open, approved protocol and established global medical advisory board Key value proposition with encouraging safety profile
Page 15
15 What is AKI associated with cardiac surgery ~26% of patients undergoing cardiac surgery suffer kidney injury Mitochondria = “batteries” for the kidney cell The kidney has the second-highest mitochondrial content and oxygen consumption in the body to fuel intense energy demands Cardiac Surgery1 Cardiopulmonary bypass starves the kidney of oxygen (ischaemia) and causes oxidative stress in kidney cells Kidney starved of oxygen Ischaemia2 Healthy mitochondria Currently no approved disease-modifying therapies Reperfusion: restores blood flow to kidney3 kidney damage caused by a massive influx of reactive oxygen species (ROS) that leads to cell death Mitochondria rupture Sudden decline in kidney function (hours) AKI Drives ICU stays, dialysis, mortality and/or progression to Chronic Kidney Disease Damaged mitochondria causes rupture of the mitochondrial membrane Source: Scurt FG et al, Kidney360 2024; Zarbock A et al, Intensive Care Med 2023; KDIGO clinical practice guidelines for AKI increases to 30-50% in high-risk patients
Page 16
16 A multicentre, double-blind, randomised, placebo-controlled study evaluating the safety and efficacy of DMX-652 in patients at high risk of AKI following cardiac surgery (n=160) Source: Mission Therapeutics MTX -652 Phase 2 protocol (FDA Study-May-Proceed, 2023); Dimerix MTX-652 development plan (2026); MAKE 30 & MAKE 90 = Major Adverse Kidney Events occurring at 30 or 90 days Proposed phase 2 clinical trial design 160 patients · 28 days on drug · 90-day follow-up · ~25 sites in US / EU / Australia Primary endpoint Secondary endpoints AKI incidence by 7 days post-surgery Screening/randomisation • Patients identified as high-risk for AKI • Stabilised on background medication pre-surgery • Standard peri-operative and post- operative care continues throughout Treatment phase Placebo N=80 DMX-652 N=80 Follow up Day 0 Day 7 Day 28 Day 90 Safety and tolerability PK MAKE30 MAKE90
Page 17
17 Strategic fit: shared renal capabilities, shared regulatory/clinical infrastructure, shared small-molecule know-how DMX-200 and DMX-652: complementary growth pillars 1. ASX release 10 March 2026; 2. ASX releases March 2024 and April 2026; 3. ASX releases 05 October 2023, 27 May 2024, 07 January 2025; 01 May 2025 and 16 June 2026; 4. ASX release 17 July 2026 1Focal Segmental Glomerulosclerosis (FSGS) rare kidney disease 1 Acute kidney injury associated with cardiac surgery 2CCR2 inhibitor that modulates inflammatory pathways involved in kidney damage 2 USP30 inhibitor designed to enhance mitophagy and mitochondrial quality control in damaged cells 3existing in-house infrastructure and global network 3 Can leverage existing expertise in clinical, regulatory, manufacturing, nephrology networks, know-how, and commercial relationships 4 4 provides a new growth engine, with an open IND, FDA clearance to proceed to Phase 2, and completed Phase 1 safety studies more advanced, near-commercialisation asset with Phase 3 fully recruited and commercial partnering activity Shared kidney disease focus Different Mechanisms of Action Shared Development Infrastructure Balanced Risk and Timing DMX-200 DMX-652
Page 18
18 Disciplined, stage-gated capital deployment focused on the clinical value inflection points1 Key potential value inflection points Asset acquisition; Patents assigned; Phase 2 ethics submission; Clinical site initiation First patient dosed in Phase 2 expected Anticipated 50% recruitment; Anticipated phase 2 interim / futility analysis Anticipated phase 2 readout Preparation for Phase 3 DMX-652 H2 2026 H1 2027 H2 2027 H1 2028 H2 2028 Paediatric recruitment completion; first patient completes open label extension study ACTION3 Phase 3 FSGS readout NDA dossier submission DMX-200 Two clinically differentiated assets in renal disease, addressing two separate high unmet need indications with independent timelines; building a steady cadence of value-creating milestones Potential for additional licensing partners in available territories 1. Based on current anticipated activities timeline Phase 3 IDMC safety review
Page 19
19 Corporate overview 1. As at 5 August 2026; 2. Past 90 trading days liquidity as at 5 August 2026; 3. Shareholder register as at 5 August 2026; 3. ASX release 16 June 2026; 4. ASX release 17 July 2026 Ticker Symbol ASX: DXB Cash Balance (Jun26)* $16.2 million Market Capitalisation1 $174 million Share price1 $0.29 Total ordinary shares on issue1 600,396,776 Average Daily Liquidity by value for past 90 trading days2 $0.85 million S H A R E P R I C E S U B S T A N T I A L S H A R E H O L D E R S 3 Position Holder Name Holding % IC 1 Mr P Meurs 91,090,374 15.3% TOTAL (TOP 5) Shareholders 150,392,268 25.1% *excluding ~$24 million to be received from : • ~AU$14 million Everest upfront payment 3 • $10 million loan facility 4
Page 20
W E L L P O S I T I O N E D TO D E L I V E R AGA I N ST ST R AT E G I C P L A N Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. +61 1300 813 321 E. investor@dimerix.com (ASX:DXB) A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on kidney diseases. ESG Statement Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.